Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
Jens Y HumrichPatrice CacoubMichelle RosenzwajgFabien PitoisetHang Phuong PhamJoel GuidouxDavid LerouxThomas VazquezGabriela RiemekastenJosef S SmolenGeorge C TsokosDavid KlatzmannPublished in: Annals of the rheumatic diseases (2022)
NCT02955615.